<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcets disease</z:e> (BD) is a <z:hpo ids='HP_0011010'>chronic</z:hpo>, relapsing, multi-system <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disorder</z:e>, clinically characterized by recurrent oral and <z:hpo ids='HP_0003249'>genital ulcers</z:hpo>, <z:mp ids='MP_0001212'>skin lesions</z:mp>, and <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Other manifestations include <z:hpo ids='HP_0001369'>arthritis</z:hpo>, a positive <z:e sem="disease" ids="C0878631" disease_type="Disease or Syndrome" abbrv="">pathergy</z:e> test, <z:hpo ids='HP_0004418'>thrombophlebitis</z:hpo>, central <z:mp ids='MP_0008912'>nervous</z:mp> system disease and gastrointestinal ulcerations </plain></SENT>
<SENT sid="2" pm="."><plain>The majority of affected individuals do not have life-threatening disease, although mortality can be associated with vascular-thrombotic and neurological manifestations </plain></SENT>
<SENT sid="3" pm="."><plain>Currently, treatment of BD is symptomatic and empirical, and is tailored according to the severity of clinical features </plain></SENT>
<SENT sid="4" pm="."><plain>In the past few years, isolated reports and case-series have been published on adult BD patients suggesting that inhibition of TNF-alpha is a promising therapeutic approach for severe ocular and various extra-ocular manifestations, including central <z:mp ids='MP_0008912'>nervous</z:mp> system involvement </plain></SENT>
<SENT sid="5" pm="."><plain>In this study we present our promising experience with Etanercept therapy in <z:hpo ids='HP_0003621'>juvenile-onset</z:hpo> BD patients, characterized by refractory multiorgan involvement </plain></SENT>
</text></document>